TY - JOUR

T1 - Feasibility and safety of transcaval transcatheter aortic valve implantation

T2 - A multicentre European registry

AU - Costa, Giulia

AU - De Backer, Ole

AU - Pilgrim, Thomas

AU - Kasel, Markus

AU - Redwood, Simon

AU - Aminian, Adel

AU - Lanz, Jonas

AU - Michel, Jonathan

AU - Patterson, Tiffany

AU - Windecker, Stephan

AU - Prendergast, Bernard

AU - Greenbaum, Adam B.

AU - Søndergaard, Lars

PY - 2020

Y1 - 2020

N2 - Aims: A transfemoral transarterial approach is considered the preferable access route for transcatheter aortic valve implantation (TAVI), followed by a transaxillary/subclavian TAVI approach. However, these approaches may not be an option in all patients. This study aimed to report the initial European experience with transfemoral transcaval TAVI. Methods and results: Data on 50 patients treated by transcaval TAVI in five European centres were collected and analysed according to the Valve Academic Research Consortium (VARC)-2 definitions. The study population had a mean age of 78.7±8.0 years and a high surgical risk profile (median STS risk score 6.1%, interquartile range 3.0-11.2%). Transcaval access was successful in 49 out of 50 patients and device success was obtained in 94% of cases. Closure of the caval-aortic puncture site with a nitinol cardiac occluder was successful in all cases without need for emergent surgery. One patient received additional sealing of the aortic puncture site with a covered stent one day post TAVI due to a gradual haemoglobin drop of 3 g/dL. VARC-2-defined life-threatening bleeding and major vascular complications possibly related to transcaval access were 4% and 10%, respectively. There were no bleeding or vascular complications after discharge. At 30 days, the clinical efficacy endpoint was reached in 88% of patients. Conclusions: Transfemoral transcaval access proved to be a feasible and safe TAVI approach for highrisk patients with severe aortic stenosis not suitable for transfemoral or transaxillary/subclavian transarterial access.

AB - Aims: A transfemoral transarterial approach is considered the preferable access route for transcatheter aortic valve implantation (TAVI), followed by a transaxillary/subclavian TAVI approach. However, these approaches may not be an option in all patients. This study aimed to report the initial European experience with transfemoral transcaval TAVI. Methods and results: Data on 50 patients treated by transcaval TAVI in five European centres were collected and analysed according to the Valve Academic Research Consortium (VARC)-2 definitions. The study population had a mean age of 78.7±8.0 years and a high surgical risk profile (median STS risk score 6.1%, interquartile range 3.0-11.2%). Transcaval access was successful in 49 out of 50 patients and device success was obtained in 94% of cases. Closure of the caval-aortic puncture site with a nitinol cardiac occluder was successful in all cases without need for emergent surgery. One patient received additional sealing of the aortic puncture site with a covered stent one day post TAVI due to a gradual haemoglobin drop of 3 g/dL. VARC-2-defined life-threatening bleeding and major vascular complications possibly related to transcaval access were 4% and 10%, respectively. There were no bleeding or vascular complications after discharge. At 30 days, the clinical efficacy endpoint was reached in 88% of patients. Conclusions: Transfemoral transcaval access proved to be a feasible and safe TAVI approach for highrisk patients with severe aortic stenosis not suitable for transfemoral or transaxillary/subclavian transarterial access.

KW - Aortic stenosis

KW - Other

KW - TAVI

U2 - 10.4244/EIJ-D-19-00797

DO - 10.4244/EIJ-D-19-00797

M3 - Journal article

C2 - 31659987

AN - SCOPUS:85083074515

VL - 15

SP - E1319-E1324

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 15

ER -